000 06244nam a22004335c 4500
999 _c5939
_d5939
001 5939
003 ES-MaUEC
005 20200615123839.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 180920s2019 si a s |||| 0|eng d
020 _a9789811053115
024 7 _a10.1007/978-981-10-5311-5
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRM666
_b.A45T44 2019EB
245 1 4 _aThe Therapeutic Use of N-Acetylcysteine (NAC) in Medicine
_cedited by Richard Eugene Frye, Michael Berk.
264 1 _aSingapore
_bSpringer Singapore :
_bImprint: Adis
_c2019.
300 _aXII, 394 páginas 29 ilustraciones, 21 ilustraciones a color
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 0 _aMedicine (Springer-11650)
505 0 _a1. History of N-acetylcysteine -- Part I. The Basic Science of NAC -- 2. Neurotransmitter Systems: glutamate -- 3. Neurotransmitter Systems: Dopamine -- 4. Oxidative Stress in Psychiatric Disorders -- 5. Mitochondrial Metabolism -- 6. Apoptosis -- 7. Inflammation -- Part II. The Clinical Use of NAC -- 8. Clinical Trials on N-Acetylcysteine -- 9. N-Acetylcysteine in the Poisoned Patient -- 10. The use of NAC as a Chelator for Metal Toxicity -- 11. Application of N-Acetylcysteine in Neurological Disorders -- 12. Application of N-Acetylcysteine in Psychiatric Disorders -- 13. Clinical Treatment of Addictive Disorders with N-Acetylcysteine -- 14. The Clinical Use of N-Acetylcysteine for the Treatment and Protection Against Renal Disease -- 15. Application of N-Acetylcysteine in Pulmonary Disorders -- 16. The Clinical Use of N-Acetylcysteine in Cardiology -- 17. The Clinical Use of N-acetylcysteine in Gastrointestinal Disorders -- 18. The Clinical Use of N-Acetylcysteine in Other Medical Disorders -- 19. The Physiological Effects of N-Acetylcysteine in Clinical Studies -- 20. Cysteine/Glutathione Deficiency: A Significant and Treatable Corollary of Disease -- 21. Pharmacology, Formulations and Adverse Effects.
520 3 _aFocusing on the practical use of N-Acetyl-Cysteine (NAC) in medicine, this book provides a comprehensive review of the basic biological and clinical studies documenting its benefits in treating medical disease. NAC is perhaps best known as an antidote for acetaminophen, but its therapeutic effect in a wide range of medical diseases has recently been realized. In addition to its well recognized use in radiological contrast prophylaxis for renal disease and pulmonary disorders, studies have suggested significant promise in psychiatric and neurological disorders such as addiction, Alzheimer’s disease, ataxia, autism, bipolar disorder, depression, epilepsy, neuropathy, obsessive-compulsive disorder, schizophrenia, traumatic brain injury and trichotillomania in addition to promising studies in audiology, cardiology, exercise physiology, gastroenterology, hematology, infectious disease, infertility and ophthalmology. Given the promising studies for a wide range of medical conditions, coupled with a excellent safety profile, the potential for NAC in the treatment of human disease appears considerable. Dr Leonore A Herzenberg from Stanford University, a pioneer of redox physiology and the use of NAC, provides a succinct history of the development of the therapeutic use of NAC for medical disease. This is followed by a series of basic science chapters outlining the role of NAC in important physiological processes, including modulation of dopamine and glutamate neurotransmitter systems, redox and mitochondrial metabolism, apoptosis and inflammation. The last section of the book is dedicated to clinically oriented chapters that comprehensively review the literature on medical disorders in which NAC has been found to be effective, including toxicity and cardiovascular, gastrointestinal, neurological, psychiatric, pulmonary and renal disorders. Each chapter reviews the theoretical biological mechanisms of NAC for the specific diseases reviewed, rates the clinical studies using a standardized criteria in order to provide an objective level of evidence and grade of recommendation for the use of NAC for specific medical conditions and outlines the ongoing clinical trials examining NAC for the treatment of specific diseases. Final chapters review the clinical evidence verifying that specific theoretical biological mechanisms are actually being targeted by NAC in medical disease. Studies on the pharmacology, formulation and potential adverse effects of NAC are also reviewed. A final chapter synthesizes the clinical studies to suggest that the effectiveness of NAC may signal a new basic physiological disorder, glutathione deficiency, which may be an important pathophysiological mechanism of many diseases. Dr. Richard Frye is the Chief of Neurodevelopmental Disorders at the Barrow Neurological Institute at Phoenix Children’s Hospital and Professor of Child Health at the University of Arizona College of Medicine - Phoenix. Professor Michael Berk is a NHMRC Senior Principal Research Fellow, and is Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health in Melbourne Australia. .
988 _aPrimersemestre_2019_Medicine
650 1 4 _aPharmacotherapy.
_0http://scigraph.springernature.com/things/product-market-codes/H69000
_9549171
650 2 4 _aPharmacology/Toxicology.
_0http://scigraph.springernature.com/things/product-market-codes/B21007
_9547531
653 0 _aToxicology.
700 1 _aFrye, Richard Eugene.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aBerk, Michael.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9789811053108
776 0 8 _iPrinted edition:
_z9789811053122
776 0 8 _iPrinted edition:
_z9789811338526
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-10-5311-5
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0